Skip to main content
Premium Trial:

Request an Annual Quote

Applied Precision Signs Distribution Deal with GeneScan Europe

NEW YORK, March 19 – Applied Precision of Issaquah, Wash., said Monday that Freiburg, Germany-based GeneScan Europe had been given the rights to exclusively distribute its ArrayWorx Microarray Scanner in Europe, Australia, and New Zealand.

"GeneScan is a major player in applied molecular biology in Europe, which will provide invaluable assistance to us in expanding our market share in these countries," Joe Ahladis, vice president of sales, marketing, and customer service for Applied Precision, said in a statement.

GeneScan’s subsidiary BioChip Technologies currently uses the ArrayWorx scanner for higher density arrays. The company uses its own microarray reader, Biodetect, for lower density arrays.

Terms of the deal were not disclosed, but the companies said it was a “long-term” partnership.

GeneScan Europe, one of 13 biotechnology companies within the GeneScan group, provides products and services in applied molecular biology and develops customized biochips with low to medium spot densities.

Applied Precision develops measurement, analysis, and process control systems for biomedical and biotechnology imaging and analysis systems. Harvard University’s Bauer Center for Genomic Research is one of the users of ArrayWorx.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.